

# Index

- abstinence, 51
  - beneficial effects of, 20
- acute psychotic symptoms, 122
- acute toxic psychosis, 140
- addiction, methamphetamine
  - CBT, 170
  - coerced treatment, 170
  - contingency management, 170
  - outcomes, 169–170
  - treatment, 169–170
- adolescence, cannabis use among,
  - schizophrenia in, 152–153
- Advisory Committee on the Misuse of Drugs (ACMD), 52
- alcohol use
  - as DD element in Europe, 232–233
  - in older people, 104–105
    - early-onset category, 106
    - excessive alcohol use, complications of, 106–107
    - media representation of information on, 104–105
    - problem drinkers, 106
    - sensible limits, 106
  - schizophrenia people, within mental health service settings, 22–23
- alcohol and mood disorders, 76–85, *See also* Medication
  - harm, alcohol and mental illness, 76–77
  - presentation, 77–78
    - alcohol use, 78
    - anaemia, 77
    - appetite, 77
    - early morning waking, 77
    - loss of libido, 78
    - Wernicke–Korsakoff syndrome, 77
- amphetamines, 10, 15, 116–118, 122, 140
- anticholinergic substances, 9
- antidepressants, 32, 78
- antipsychotics, 32, 122–123
- antisocial personality disorders, 18, 89
- Assertive Community Treatment (ACT)
  - model, 67, 205
- assessment, 6–8
  - general considerations in, 5
  - personality disorders, 92–93
    - comprehensive assessment, 92
    - structured treatment models, 92
- assortative mating, 10
- Australasia, DD in, 212–227
  - Australia's responses to, 221
  - Australian health care system, structure of, 221
- barriers to better outcomes for, 217–218
  - contributing factors, 217–218
- 'Can Do' – managing mental health and substance use in general practice, 223–224
- 'Communities of Youth Services' (CYS)
  - activities, 224
- consumer and carer demand, 212–213
- co-occurring disorders, treatment for, 216–217
- drivers for system change, 212
- harms associated with, 213–216
- headspace, 224–225
- improved services for people with drug and alcohol problems and mental illness, 223
- indigenous Australians, 218–219
- mental health services in Australia (MHCA), 212–213
- national comorbidity initiative, 221–223
  - completed projects, 222
  - current projects, 222
- national level responses to DD, 221
- prevalence of
  - estimation, 214
  - forensic populations, 216
  - general population, 214
  - in persons in primary care, 215
  - in persons receiving treatment for a substance use disorder, 215

- Australasia, DD in (*cont'd*)  
 prevalence, 213  
 in rural Australia, contributing factors,  
 217–218  
 attitudinal, 220  
 service access, 220  
 structural, 220  
 workforce, 220  
 rural and remote regions of Australia,  
 219–220  
 state level responses, 225–227  
 Victoria's responses to dual diagnosis,  
 225–226  
 unwanted outcomes associated with,  
 213–216
- 'Baby boomers', 103  
 benzodiazepines, 108–109  
 blood-borne infections, 179–180  
 borderline personality disorders (BPD), 89  
 in women, 131–132  
 bupropion, 169
- Caldicott principles, 42  
 cannabis use and psychosis, 118, 140,  
 147–159, 177  
 in adolescence, 152–153  
 among schizophrenia people, 151  
 drug-induced psychosis, 152  
 exacerbating psychotic illness, 154  
 interventions for, 155–158  
 cannabis and psychosis intervention  
 (CAP), 156  
 group programmes, 156–157  
 motivational interviewing (MI),  
 155–156  
 two-session standard psychiatric  
 interview, 156  
 legal issues, 148, *See also* penalties *here*  
 Misuse of Drugs Act 1971, 148  
 links between, 151–155  
 neurophysiological changes, 155  
 penalties  
 for adults in possession of, 149  
 for dealing, 149  
 for possession, 149  
 for production, 149  
 for supply, 149  
 for trafficking, 149  
 for young people in possession of, 149  
 physical effects, 150  
 prodromal symptoms of psychosis  
 (PROD), 153  
 psychological effects, 149–150  
 risks associated with, 150  
 safety issues, 150  
 self-medication hypothesis, 154  
 stress-vulnerability theory or interaction  
 hypothesis, 154  
 tetrahydrocannabinol (THC), 148  
 ways of affecting the user, 148–149  
 ways of using, 148
- Care Programme Approach (CPA), 42, 91  
 Cartesian philosophical concept, 187  
 causal relationship, public health and DD,  
 178–180  
 children, MA in, 167  
 cholinergic pathways, 11  
 chronic hallucinosis induced by substance  
 use, 142  
 clinical risk assessment, 39–41  
 demographic information in, 40  
 harm reduction strategies, 40  
 recovery-based approach, 40  
 clozapine, 126  
 cocaine, 118  
 cocaine hallucinosis, 118  
 cocaine-induced paranoia, 121  
 cocaine-induced psychosis, 118  
 cocaine-using schizophrenia people, 19  
 Cognitive behaviour therapy (CBT),  
 71–72  
 Cognitive behavioural integrated treatment  
 (C-BIT), 68  
 commissioning services for users with DD,  
 243–248  
 background, 243–244  
 Drug Action Team (DAT), 246  
 history of commissioning, 244–246  
 'internal market', 244  
 implications for, 246–248  
 Local implementation Team (LIT), 246  
 overview and scrutiny committees (OSCs),  
 246  
 'post code lottery', 244  
 primary care trusts (PCTs), 244  
 world class commissioning, 245–246  
 common aetiology, 10  
 co-morbid personality disorder, 94  
 co-morbid psychotic illness, 16  
 co-morbid substance misuse, 190  
 'Comorbidity', 4  
 comorbidity between psychotic illness and  
 substance misuse, 18  
 comorbidity or complexity, question of,  
 186–194, *See also* Primary care  
 perspective  
 Comprehensive, Continuous, Integrated  
 System of Care (CCISC) model, 182  
 'Communities of Youth Services' (CYS)  
 activities, 224  
 conduct disorder, 18  
 consumer perspectives, 27–35, *See also*  
 Psychiatric wards  
 diagnosis, 29, 32  
 drug and alcohol services and mental  
 health, contrasts in, 30–32  
 approach to 'therapy', 30–31  
 staff, make-up of, 30

- dual diagnosis and policy, 33–35
  - issues in, 34
- human experience and medicine, 27–28
- human rights, 28–29
- involuntary patient admission, 30–32
- language of mental illness, 28
- treatment, 28–29, 32–33
- two worlds, 29–30
  - voluntary in-patient admission, 30–32
- contingency management, 72
- co-occurring disorders
  - in Australasia, treatment for, 216–217
  - treatment for, 207
- ‘Cradle to the grave’ care, 190
- ‘DD aware’, 33
- Data Protection Act 1998, 42
- definition, 4–5
- deinstitutionalisation effects, schizophrenia
  - population substance misuse, 20–21
- delirium tremens (DT), 142
- depression, 9, 79
- ‘Demographic transition’, 102–103
- detoxification, 7, 10
- diagnosis, consumer perspectives, 28–29, 32
- discrepancy development, in motivational interviewing (MI), 60
- disulfiram, 79
- domestic violence, DD and, 135
- dopamine, 121, 140–141
- dopaminergic neurotransmitter system, 17
- drinking among schizophrenia, 19
- Drug Misuse Act 1971, 103
- drug-induced psychosis, 139–144
  - acute toxic psychosis, 140
  - cannabis in, 152
  - cannabis psychosis, 140
  - prevalence of DD, 139–140
  - psychotic illness and, 142–144
    - anxiety reactions, 143
    - chronic hallucinosis induced by
      - substance use, 142
      - drug-induced relapse, 142
      - intoxication, 142
      - pathoplastic reactions, 142
      - withdrawal states, 142
  - ‘recreational’ drugs, 141
  - self-medication, 141
  - stimulant use and, 117–121
    - cocaine-induced paranoia, 121
    - dopamine, 121
    - flashbacks*, 120
    - Khat-related illness difficult, 120
    - methamphetamine psychosis, 120
    - positive symptoms, 119
    - sensitisation to substances, 120
    - short-lived schizophreniform illness, 120
  - substance use and psychosis, relationship between, 140–141
  - true drug-induced psychosis, 143
- drug-induced relapse of functional psychotic illness, 142
- drug-related harm among mentally ill people, reducing, 51–56, *See also* Harm reduction approaches
  - definitor, 52–53
  - evidence-based approaches, 51
  - future, question of, 55–56
  - harm reduction, 52–53
  - interventions and approaches, 51–52
  - with mentally ill individuals, 53–54
    - five-stage intervention model, 53
    - motivation-based approaches, 53
  - needle and syringe exchange programmes, 52
- drugs use, in schizophrenia people, within mental health service settings, 22–23
- DSM III-R substance abuse disorder, 15
- dual diagnosis, 179–180
- dysphoria, 168
- ecstasy users, 122
  - poly substance use among, 119
  - psychosis in, 119
- education development, 253–254
- effective treatments for substance misuse, 91
  - principles, 92
- empathy expression, in motivational interviewing (MI), 60
- Epidemiologic Catchment Area (ECA) study, 5, 14
- Europe, DD in, 230–241
  - Czechoslovakia, 231
  - elements of DD, 232
    - alcohol, 232–233
    - care and treatment responses, 235–237
    - HIV/AIDS, 234–235
    - illicit drugs, 233
    - problems and solutions, 237–240
    - triple diagnosis, 234–235
  - Germany, 231
  - historical context, 230–232
  - poverty and mental health, 231
  - social context, 230–232
  - Soviet Union, 230
- evidence-based treatment, 69
- existing psychotic illnesses, stimulants use by, 122–124
- explanatory models for dual diagnosis, 13–23
- families
  - interventions, 72
  - women with DD, impact on, 133–134
    - Hidden Harm report, 133
- female prison service, DD within, 135–136, *See also* Women and DD

- five-stage intervention harm reduction model, 53  
*flashbacks*, 120  
 fluoxetine, 169
- gender differences in DD, 131–133  
 gender-specific services, 136–137  
 general practice care, 190–191  
 General Practice Research Database (GPRD), 177  
 genetic factors, and dual diagnosis, relationship, 17  
 group therapies, 70–71
- hallucination, 169  
 hallucinogen misuse, 15  
 harm reduction approaches, 52–53  
   definition, 52–53  
   with mentally ill individuals, 53–54  
     five-stage intervention model, 53  
     motivation-based approaches, 53  
   needle and syringe exchange programmes, 52  
 harm, alcohol and mental illness, 76–77  
 Hepatitis B (HBV), 179  
 Hepatitis C (HCV), 179  
 holistic risk assessment, 42  
 human experience and medicine, 27–28  
 human immunodeficiency virus (HIV), 180  
 human rights, consumer perspectives, 28–29  
 hypersomnia, 168  
 hypotheses, 8–11  
   common aetiology, 10  
   dual primary diagnosis, 10  
   mental illness is primary and substance misuse is secondary, 8  
   primary substance misuse with psychiatric consequences, 9
- imipramine, 169  
 indigenous Australians, 218–219  
 indigenous substance use, 218–219  
 individual therapies, 70  
 infections and DD, 181–183  
   blood-borne infections, 179–180  
   causal relationship, 178–180  
     criteria for, 179  
   dual diagnosis, 179–180  
   epidemiology, 176–178  
   ethnicity, 178  
   Hepatitis B (HBV), 179  
   Hepatitis C (HCV), 179  
   human immunodeficiency virus (HIV), 180  
 infections, 181–183  
   CCISC model, 182  
   intervention, 181–183  
   needle exchange programmes (NEP) in prevention, 182  
   prevention, 181–183  
     primary prevention, 181  
     secondary prevention, 181–182  
     ‘stages of change’ model, 182–183  
     system-wide approach, 182  
     tertiary prevention, 182  
   intravenous drug use (IVDU), 177  
   self harm, 177  
   suicide, 177  
   treatment for BBV, 180–181
- initial problems in dual diagnosis, 16–17  
 difficulties in establishing temporal sequence, 16  
 in-patient care, 256–257  
 integrated care models, 203–204  
 Intensive Outpatient Programs (IOP), 205  
 intoxication  
   in functional psychotic illness, 142  
   in MA, 168–169  
 intravenous drug use (IVDU), 177  
 ‘Involuntary treatment’, 32–33
- ketamine effect on people with and without schizophrenia, 123  
 Khat-related illness difficult, 120
- language of mental illness, 28  
 legal issues in cannabis use, 148  
 long-term psychotic illness, 118
- media representation of information on alcohol, 104–105  
 medication and dual diagnosis, 78–80  
   antidepressants, 78  
   disulfiram, 79  
   psychotropic medication, 78  
   selective serotonin reuptake inhibitors (SSRIs), 79  
 mental health and substance misuse care, 192–193  
 mental illness, stimulants and, 121–122  
   ecstasy, 122  
 mental illness/health problems, 3–6  
   initial assessment, 7  
 methamphetamine (MA) and mental health, 120, 163–171  
   addiction  
     outcomes, 169–170  
     treatment, 169–170  
   anxiety, 169  
   brief intervention by physicians, 166  
   case studies, 164–165  
   in children, 167  
   community based programs, 166  
   continuation of, 165–168  
   hallucination, 169  
   initiation, 165–168  
   interpersonal violence, 167  
   intoxication, 168–169  
   mood disturbance, 169

- paranoia, 169
    - in pregnant women, 166
    - psychiatric illness, 168–169
    - screening, 166
    - withdrawal, 168–169
  - 3,4-Methylenedioxymethamphetamine, 141
  - methylenedioxyamphetamine (MDA), 116
  - methylenedioxy-N-methamphetamine (MDMA), 116
  - Michigan Alcohol Screening Test (MAST-G), 107
  - Misuse of Drugs Act 1971, 97, 148
  - mood disorders, 76–85, *See also* Alcohol and mood disorders
  - motivational approaches, 69–70
  - motivational interviewing (MI), 58–65, 155
    - description, 58–61
    - full-blown resumption of previous behaviour, 60
    - opening strategies, 61
      - affirming, 61
      - open-ended questions, 61
      - reflective listening, 61
      - summarising, 61
    - principles, 60
      - developing discrepancy, 60
      - expressing empathy, 60
      - roll with resistance, 60–61
      - supporting self-efficacy, 61
    - short-lived resumption of previous behaviour, 60
    - ‘Stages of Change’ model, 59
  - motivation-based harm reduction approach, 53
  - National Toxicology Program Center for the Evaluation of Risks to Human Reproduction (NTP-CERHR 2005), 167
  - needle exchange programmes (NEP), 182
  - neurobiological basis of dual diagnosis, question of, 17–18
  - neuroleptic (‘antipsychotic’) medications, 32
  - neurophysiological changes, 155
  - ‘No Right Door’ policy, 34
  - ‘NoWrong Door’, 33
  - non-cocaine-using schizophrenia people, 19–20
  - non-ecstasy users, poly substance use among, 119
  - North America, DD in, 199–207
    - challenges, 206–207
    - co-occurring disorders, treatment for, 207
    - historical context, 200–201
    - insurance programmes, 202
    - issues, 206–207
    - lifetime substance abuse disorders, 199
    - MICA (Mentally ill chemical abusers) models, 201
    - prevalence, 199–200
    - public policy considerations, 201–203
    - quality and accessibility to care, 202
    - research, 205–206
    - socio-cultural considerations, 201–203
    - treatment approaches, 203–205
      - Assertive Community Treatment (ACT) model, 205
      - integrated care models, 203–204
      - Intensive Outpatient Programs (IOP), 205
      - obstacle to, 203
      - partial hospitalisation, 205
      - self-help group approach, 205
      - twelve-step programmes, 205
  - olanzapine, 126
  - older people, DD in, 102–113
    - alcohol use among, 104–106
      - early-onset category, 106
      - excessive alcohol use, complications of, 106–107
    - media representation of information on, 104–105
    - problem drinkers, 106
    - sensible limits, 106
  - assessment, 107
  - ‘baby boomers’, 103
  - early-onset drinking, case study, 109–112
  - an increasing population, 102–103
  - late-onset drinking, case study, 111–112
  - over-the-counter medication (OTC), 107–108
  - perception of old age, 105
  - policy framework, 103–104
  - prescribed medication, 108–111
    - benzodiazepines, 108–109
  - screening, 107
  - under-reporting, 107
- orofacial tardive dyskinesia, 20
- over-the-counter medication (OTC), 107–108
- paranoia, 169
- paranoid schizophrenia, 118
- pathoplastic reactions in functional psychotic illness, 142
- penalties associated with cannabis, 149
  - for adults in possession of, 149
  - for dealing, 149
  - for possession, 149
  - for production, 149
  - for supply, 149
  - for trafficking, 149
  - for young people in possession of, 149
- perception of old age, 105
- retirement, 105

- personality disorders, 4, 89–100
  - antisocial personality disorders (ASPD), 89
  - assessment, 92–93
    - comprehensive assessment, 92, 95
    - structured treatment models, 92
  - borderline personality disorders (BPD), 89
  - co-morbid personality disorder, 94
  - description, 90–91
  - dual diagnosis mediated by, 18
  - intervention approaches, 91–92
  - prevalence, 89
  - service delivery, 89–90
  - stages of change model, 93–99
    - action, 93
    - contemplation, 93
    - decision, 93
    - factors to consider, 97–98
    - guidance, 94
    - maintenance, 93
    - precontemplation, 93
    - relapse, 93
    - screening, 95–96
  - therapeutic principles, 99–100
  - treatment, 91–92
- physical effects of cannabis use, 150
- physical health care, 191–192
- policy framework, for DD in older people, 103–104
- poly substance use
  - among ecstasy users, 119
  - among non-ecstasy users, 119
  - and personality disorder, 89–100, *See also* Personality disorder
  - treatments for, 91
- post-traumatic stress disorder (PTSD), 130
  - practice, 254–257
    - mental health and substance abuse services, assessment in, 255–256
    - organisation of services, 256
    - in-patient care, 256–257
    - prevention, 254–255
    - primary care, 255
- pregnant women, MA in, 166
- prescribed medication, for older people, 108–111
  - benzodiazepines, 108–109
- presentation, alcohol and mental illness, 77–78
  - alcohol use, 78
  - anaemia, 77
  - appetite, 77
  - early morning waking, 77
  - loss of libido, 78
  - Wernicke–Korsakoff syndrome, 77
- primary care perspective on DD, 186–194
  - co-morbid substance misuse, 190
  - ‘cradle to the grave’ care, 190
  - epidemiology, 188–190
  - evidence-based approach, 190
  - general practice care, 190–191
  - limitations in, 193–194
  - mental health and substance misuse care, 192–193
  - physical health care, 191–192
  - policy framework, 188
  - potential in, 193–194
  - primary care trusts (PCTs), 244
  - substance misuse and mental illness, relation between, 189
- primary dual diagnosis, 10
- primary substance misuse with psychiatric consequences, 9–10
- prodromal symptoms of psychosis (PROD), 153
- psychiatric illness, 168–169
- psychiatric wards
  - drug and alcohol services and mental health, contrasts in, 30–32
    - approach to ‘therapy’, 30–31
    - staff, make-up of, 30
  - involuntary patient admission, 30–32
  - voluntary in-patient admission, 30–32
- psychological effects of cannabis use, 149–150
  - in adolescence, 152–153
  - among schizophrenia people, 151
  - drug-induced psychosis, 152
  - exacerbating psychotic illness, 154
  - interventions for, 155–158
    - cannabis and psychosis intervention (CAP), 156
    - group programmes, 156–157
    - motivational interviewing (MI), 155–156
    - two-session standard psychiatric interview, 156
- legal issues, 148, *See also* penalties *here*
  - Misuse of Drugs Act 1971, 148
- links between, 151–155
- neurophysiological changes, 155
- penalties
  - for adults in possession of, 149
  - for dealing, 149
  - for possession, 149
  - for production, 149
  - for supply, 149
  - for trafficking, 149
  - for young people in possession of, 149
- physical effects, 150
- prodromal symptoms of psychosis (PROD), 153
- psychological effects, 149–150
- risks associated with, 150
- safety issues, 150
- self-medication hypothesis, 154
- stress-vulnerability theory or interaction hypothesis, 154
- tetrahydrocannabinol (THC), 148
- ways of affecting the user, 148–149
- ways of using, 148

- psychological interventions, 67–73  
 ACT models, 67  
 cognitive behaviour therapy (CBT), 71–72  
 contingency management, 72  
 evidence for, 68–70  
 evidence-based treatment, 69  
 family interventions, 72  
 group therapies, 70–71  
 individual therapies, 70  
 motivational approaches, 69–70  
 nature of, 67–68  
 primary disorder, 69  
 relapse prevention, 71–72  
 secondary disorder, 69  
 type of, 67–68
- psychosis, 32  
 stimulant use and, 116–127
- psychotic illness/disorders, 16–17  
 cannabis use exacerbating, 154  
 and drug and alcohol use, 142–144, *See also*  
*under Drug-induced psychosis*  
 in general population and substance  
 misuse people, comparison, 14–16
- psychotropic medication, 78
- public health and DD, 176–184  
 blood-borne infections, 179–180  
 causal relationship, 178–180  
 criteria for, 179  
 dual diagnosis, 179–180  
 epidemiology, 176–178  
 ethnicity, 178  
 Hepatitis B (HBV), 179  
 Hepatitis C (HCV), 179  
 human immunodeficiency virus (HIV),  
 180  
 infections, 181–183  
 CCISC model, 182  
 intervention, 181–183  
 needle exchange programmes (NEP) in  
 prevention, 182  
 prevention, 181–183  
 primary prevention, 181  
 secondary prevention, 181–182  
 ‘stages of change’ model, 182–183  
 system-wide approach, 182  
 tertiary prevention, 182  
 intravenous drug use (IVDU), 177  
 self harm, 177  
 suicide, 177  
 treatment for BBV, 180–181
- public policy considerations, in North  
 America, 201–203
- ratings scales for stimulant use, 125
- recognition, 6–8  
 general considerations in, 5
- recovery-based approach, in risk assessment,  
 40
- ‘Recreational’ drugs, 141
- relapse prevention, 71–72
- research, 250–252  
 need for, 251–252
- resistance roll, in motivational interviewing  
 (MI), 60–61
- retirement, 105
- risk assessment and management, 39–49, *See*  
*also Clinical risk assessment*  
 principles, 41–42  
 Caldicott principles, 42  
 Care Programme Approach (CPA), 42  
 Data Protection Act 1998, 42  
 Department of Health provides (DH  
 2007), 41  
 holistic risk assessment, 42  
 process of, 42–43  
 care planning, 43  
 communication, 43  
 context, 42  
 deciding which risk factors can be  
 modified, 42  
 defining the risks, 42  
 evaluating the risks, 42  
 identifying who is at risk, 42  
 information gathering, 42  
 resource implications, 43  
 review, 43
- risk factors for addiction, 8–9
- safety issues in cannabis use, 150
- schizophrenia people, 10, 14–16, 20–22, 122  
 alcohol use, within mental health service  
 settings, 22–23  
 cannabis prevalence among, 151  
 cocaine-using, 19  
 drugs use, within mental health service  
 settings, 22–23  
 ketamine effect on, 123  
 medication side effects, 20  
 non-cocaine-using, 19–20  
 substance misuse in, 20–21  
 substances use as self-medication form,  
 19–20
- selective serotonin reuptake inhibitors  
 (SSRIs), 79
- self harm, 177
- self-efficacy support, in motivational  
 interviewing (MI), 61
- self-help group approach, for DD in North  
 America, 205
- self-medication  
 drug-induced psychosis, 141  
 hypothesis, in cannabis use, 154  
 in schizophrenia people, 19–20
- self-report, in stimulant use, 126
- sensitisation, 123  
 to substances, 120
- short-lived schizophreniform illness, 120
- significance of dual diagnosis problem,  
 5–6
- sinsemilla, 147

- social circumstances
  - leading to substance misuse in schizophrenia population, 20–21
  - social difficulties, 21–22
  - social situations, 21–22
- socio-cultural considerations, in North America, 201–203
- ‘Stages of change’ model, 59, 182–183
  - change, 183
  - contemplation, 183
  - maintenance, 183
  - pre-contemplation, 182
  - preparation, 183
  - relapse, 183
- stages of change, in personality disorders, 93–99, *See also under* Personality disorders
- stimulant use
  - clozapine, 126
  - drug-induced psychosis and, 117–121
    - positive symptoms, 119
  - implications for practice, 125–127
    - psychiatric symptoms, 125
    - ratings scales of therapeutic alliance, 125
  - mental illness and, 121–122
    - ecstasy, 122
  - olanzapine, 126
  - people with existing psychotic illnesses, 122–124
    - and psychosis, 116–127
    - self-medicating unpleasant symptoms, 126
    - self-report, 126
    - in United Kingdom, 117
      - British Crime Survey 2003/2004, 117
- stress-vulnerability theory or interaction hypothesis, 154
- substance misuse
  - among women, 130–138
  - problems, 3–4
    - assessment, 7
  - in schizophrenia population, 20–21
    - general population and, psychotic illnesses, 14–16
    - social circumstances leading to, 20–21
  - substance use and psychosis, relationship between, 140–141
  - substance Use Mental Illness Treatment Team (SUMITT) pilot, 225
  - suicide, 177
  - system-wide approach, public health and DD, 182
- terminology, 4–5
- tetrahydrocannabinol (THC), 148
- therapeutic principles, personality disorders, 99–100
- treatment, consumer perspectives, 28–29, 32–33
- triple diagnosis, 234–235
- true drug-induced psychosis, 143
- twelve-step programmes, 205
- under-reporting, of alcohol misuse in older people, 107
- United Kingdom
  - stimulant use in, 117
    - British Crime Survey 2003/2004, 117
- United States, DD in, 202–204
- Victorian Dual Diagnosis Initiative (VDDI), 225
- Wernicke–Korsakoff syndrome, 77
- withdrawal states, 142
- withdrawal, MA, 168–169
- women and DD, 130–138
  - borderline personality disorder, 131
  - complex PTSD, 131–132
  - domestic violence, 135
  - within female prison service, 135–136
  - gender differences in DD, 131–133
  - gender-specific services, 136–137
  - impact on families, 133–134
    - Hidden Harm report, 133
  - personality disorders, 131
  - PTSD, 131–132